Effects of propylthiouracil on the biodistribution of an iodine-131-labeled anti-myeloid antibody in normal dogs: dosimetry and clinical implications.
Despite the use of near maximal doses of chemoradiotherapy, tumor recurrence remains the most frequent cause of treatment failure following marrow transplantation for leukemia. We have previously demonstrated that it is possible to selectively deliver radiation to the marrow space. In that study an initial short half-life of the radionuclide was observed. In this study we attempted to prolong the retention of the radioiodine in marrow through the use of propylthiouracil (PTU). When administered to normal dogs, PTU pretreatment resulted in improved marrow localization of 131I-labeled DM-5. There was no appreciable loss of activity from the marrow during the 2-4 hr postinjection time interval; a finding in contrast to the control animals where marrow activity declined a mean 45 +/- 0.5% over the same time period. Additionally, in contrast to controls, a rise in plasma trichloroacetic acid (TCA) nonprecipitable activity was not demonstrated in the PTU treated group during this 2-4 hr period. These results suggest that PTU's inhibition of deiodinases resulted in longer residence time of the radionuclide in its target tissue without adversely affecting distribution to non-target organs.
Bianco
J A
JA
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Brown
P A
PA
Durack
L
L
Badger
C
C
Bernstein
I
I
Eary
J
J
Durham
J
J
Fisher
D
D
Sandmaier
B
B
Schuening
F
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D001853:Bone Marrow / Q000000981:diagnostic imaging* / Q000276:immunology / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D004285:Dogs; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D011441:Propylthiouracil / Q000494:pharmacology*; D011829:Radiation Dosage; D011877:Radionuclide Imaging; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011441:Propylthiouracil